Davari Majid, Sorato Mende Mensa, Fatemi Behzad, Rezaei Soheila, Sanei Hamid
Associate Professor, Department of Pharmacoeconomics and Pharma Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
PhD Candidate, Department of Pharmacoeconomics and Pharma Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
ARYA Atheroscler. 2022 May;18(3):1-12. doi: 10.48305/arya.2022.24252.
Ischemic heart disease (IHD) is the first cause of mortality in the world. Stable coronary artery disease (CAD) is the most common IHD. Medical therapy (MT), percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG) are three strategies for the management of this disease. The main aim of this study was the comparison of MT with PCI or CABG in terms of cardiovascular (CV) mortality, myocardial infarction (MI), unplanned revascularization (UR), stroke, and freedom from angina in managing stable CAD.
The Cochrane Central Register of Controlled Trials, Embase, PubMed, and Scopus were searched. Two reviewers independently appraised the titles and abstracted data of the identified studies. After the Full-text reviewing phase, eligible studies were analyzed through the random-effect meta-analysis method. Finally, a sensitivity analysis was conducted for the robustness of findings.
Nine randomized controlled trials (RCTs) were included. The pooled RR of CV mortality associated with MT compared with PCI and CABG was 1.22 and 1.385, respectively. Overall, The RR of MT associated with MI, UR, stroke, and freedom from angina compared with PCI was 1.001, 1.151, 0.799, and 0.801, respectively.
Our results revealed no statistically significant difference between MT and PCI in terms of studied primary outcomes. The findings also highlighted that there is no statistically significant difference between MT and CABG in terms of CV mortality.
缺血性心脏病(IHD)是全球首要死因。稳定型冠状动脉疾病(CAD)是最常见的缺血性心脏病。药物治疗(MT)、经皮冠状动脉介入治疗(PCI)和冠状动脉旁路移植术(CABG)是治疗该疾病的三种策略。本研究的主要目的是比较药物治疗与经皮冠状动脉介入治疗或冠状动脉旁路移植术在治疗稳定型CAD时的心血管(CV)死亡率、心肌梗死(MI)、非计划性血管重建(UR)、中风以及无心绞痛方面的差异。
检索了Cochrane对照试验中心注册库、Embase、PubMed和Scopus。两名评价者独立评估所识别研究的标题并提取数据。在全文评审阶段之后,通过随机效应荟萃分析方法对符合条件的研究进行分析。最后,进行敏感性分析以检验研究结果的稳健性。
纳入了9项随机对照试验(RCT)。与经皮冠状动脉介入治疗和冠状动脉旁路移植术相比,药物治疗相关的心血管死亡率合并相对危险度(RR)分别为1.22和1.385。总体而言,与经皮冠状动脉介入治疗相比,药物治疗相关的心肌梗死、非计划性血管重建、中风以及无心绞痛的RR分别为1.001、1.151、0.799和0.801。
我们的结果显示,在研究的主要结局方面,药物治疗与经皮冠状动脉介入治疗之间无统计学显著差异。研究结果还强调,在心血管死亡率方面,药物治疗与冠状动脉旁路移植术之间无统计学显著差异。